Why is accessibility such a crucial consideration of open access publishing, and how can we ensure content is sufficiently accessible?
The Association of the British Pharmaceutical Industry (ABPI) has said that it wants to take transparency to the next level, and has committed to making clinical research more accessible and understandable across the pharmaceutical industry.
Evidence is essential for identifying treatment priorities and developing polices, said Claire Allen of Evidence Aid, at Evidence-Based Medicine Live (EBMLive), which took place on 15–17 July in Oxford, UK.
Last week’s ISMPP-U webinar ‘Open Access and Medical Publishing’, developed by the Medical Publishing Insights & Practices (MPIP) initiative and Open Pharma and moderated by LaVerne Mooney (Pfizer) and Chris Winchester (Oxford PharmaGenesis), aimed to define the key elements of open access policies, to provide insight into the changing publishing environment and to understand the perspectives of non-commercial and commercial stakeholders on open access publishing.
Featuring pharma taking the lead on sharing clinical trial results, where preprints end up, and the identity of peer reviewers.
The problem of bias, both subconscious and conscious, in medical research was a consistent theme through many of the talks delivered at Evidence Live this year. As the first post in a series on the talks from Evidence Live, this article will give an overview of what evidence based medicine actually is. In his session, … Continue reading Evidence Live – what is evidence-based medicine?
Patient engagement in medical research is a priority for the pharmaceutical industry; however, patient involvement in publications is rare.